What is the 13F Pro Quality Score for PCSA?

13F Pro ranks Processa Pharmaceuticals, Inc. (PCSA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PCSA's current score at https://13fpro.ai/research/PCSA (free sign-up required for the full ranking).

Where does 13F Pro source PCSA data?

All Processa Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Processa Pharmaceuticals, Inc. files with the SEC under CIK 1533743. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PCSA in?

Processa Pharmaceuticals, Inc. (PCSA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PCSA research updated on 13F Pro?

PCSA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Processa Pharmaceuticals, Inc.(PCSA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1533743 PCSA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PCSA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Processa Pharmaceuticals, Inc. (PCSA), a Healthcare sector company. PCSA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Processa Pharmaceuticals, Inc. reports net income of $-3.4M, free cash flow of $-3.6M. Top institutional holders of PCSA by reported 13-F value include Connective Capital Management,, Stonepine Capital Management,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. PCSA trades on the Nasdaq exchange and files with the SEC under CIK 1533743. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PCSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Processa Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-3.4M

Free Cash Flow

Q1 2026

$-3.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 $0.00FY23 —FY24 —FY25 —

Net Income

-14.5% YoY

$-13.6MFY 2025

FY21 $-11.4MFY23 $-11.1MFY24 $-11.9MFY25 $-13.6M

Operating Income

-16.1% YoY

$-14.0MFY 2025

FY21 $-12.1MFY23 $-11.5MFY24 $-12.1MFY25 $-14.0M

EPS (Diluted)

+89.3% YoY

$-10.36FY 2025

FY21 —FY23 $-8.48FY24 $-96.78FY25 $-10.36

Total Assets

+142.0% YoY

$7.8MFY 2025

FY21 $26.5MFY23 $5.8MFY24 $3.2MFY25 $7.8M

Total Debt

—FY 2025

FY21 —FY23 —FY24 —FY25 —

Op. Cash Flow

-1.2% YoY

$-11.4MFY 2025

FY21 $-8.7MFY23 $-8.1MFY24 $-11.2MFY25 $-11.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2018	FY 2017
Revenue	—	—	—	$0.00	—	—
Net Income	$-13.6M -14.5%	$-11.9M -6.6%	$-11.1M +2.7%	$-11.4M -203.5%	$-3.8M -102.8%	$-1.9M
Operating Income	$-14.0M -16.1%	$-12.1M -5.2%	$-11.5M +5.6%	$-12.1M -168.1%	$-4.5M -151.0%	$-1.8M
EPS (Diluted)	$-10.36 +89.3%	$-96.78 -1041.3%	$-8.48	—	—	$-0.06
Total Assets	$7.8M +142.0%	$3.2M -44.2%	$5.8M -78.1%	$26.5M +112.0%	$12.5M +318.4%	$3.0M
Total Debt	—	—	—	—	$230.0K -90.6%	$2.4M
Operating Cash Flow	$-11.4M -1.2%	$-11.2M -39.5%	$-8.1M +7.5%	$-8.7M -135.1%	$-3.7M -124.1%	$-1.7M

AI Insight: PCSA Financial Trends

Processa generates zero revenue across all eight quarters, burning ~$3M per quarter with equity eroding to $3M in Q1 2026.

• No revenue recorded in any quarter from Q2 2024 through Q1 2026 — company remains entirely pre-commercial.

• Equity declined from $6M in Q2 2024 to $3M in Q1 2026, halving over eight quarters of losses.

• Operating cash outflows ranged from $-2M to $-4M per quarter, showing no meaningful improvement in cash burn rate.

⚠ Equity at $3M in Q1 2026 — at current ~$3M quarterly burn, runway is critically short without new financing.

⚠ Op income widened to $-4M in Q4 2025 and Q2 2025 — watch for further expense acceleration.

AI Insight: PCSA Ratio Trends

Data is almost entirely absent — only one data point (ROE of -199.9% in Q2 2024) exists, making meaningful trend analysis impossible.

• ROE stood at -199.9% in Q2 2024, the sole available metric across all reported periods.

• All other ratio fields — OpMargin, NPM, ROA, ROIC, D/E — are missing across every reported quarter.

⚠ The lone ROE reading of -199.9% in Q2 2024 signals deep losses relative to equity; future disclosures needed to assess trajectory.

Get alerted when PCSA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Processa Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PCSA

Connective Capital Management, LLC
$178.6K70,736 sh
Stonepine Capital Management, LLC
$138.9K55,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$62.8K24,908 sh
VANGUARD CAPITAL MANAGEMENT LLC
$32.1K12,729 sh
VANGUARD FIDUCIARY TRUST CO
$27.4K10,857 sh
UBS Group AG
$6.4K2,531 sh
Tower Research Capital LLC (TRC)
$2.3K918 sh
CITIGROUP INC
$35.0014 sh
JONES FINANCIAL COMPANIES LLLP
$17.007 sh
WELLS FARGO & COMPANY/MN
$15.006 sh

Fund	Value	Shares
Connective Capital Management, LLC	$178.6K	70,736
Stonepine Capital Management, LLC	$138.9K	55,000
GEODE CAPITAL MANAGEMENT, LLC	$62.8K	24,908
VANGUARD CAPITAL MANAGEMENT LLC	$32.1K	12,729
VANGUARD FIDUCIARY TRUST CO	$27.4K	10,857
UBS Group AG	$6.4K	2,531
Tower Research Capital LLC (TRC)	$2.3K	918
CITIGROUP INC	$35.00	14
JONES FINANCIAL COMPANIES LLLP	$17.00	7
WELLS FARGO & COMPANY/MN	$15.00	6

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PCSA on your watchlist

Track score changes the day Processa Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PCSA a good stock to buy?

13F Pro's AI-powered analysis of Processa Pharmaceuticals, Inc. (PCSA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PCSA are available on the PCSA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PCSA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PCSA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Processa Pharmaceuticals, Inc.'s investment landscape.